

# IHI Call Days | Call 12

## IHI EMBRACE

EndoMetriosis : for a Better Recognition, Access and Care Enhancement

Contact person name: Henri Souchay

Organisation: GE HealthCare

E-mail: [henri.souchay@gehealthcare.com](mailto:henri.souchay@gehealthcare.com)

Link to the IHI brokerage platform:

- [IHI EMBRACE](#)
- [Participant profile](#)


# Challenges and objectives

**Endometriosis:** endometrial tissue growing outside of the uterus creates a chronic, inflammatory disease affecting quality of life and fertility with high societal cost

**Prevalence:** up to 10% of women of reproductive age, 170M+ worldwide

Patient pathway incurs long delays & challenges to access adequate care:

- **root cause** of disease not understood: links to uterine motility, environment, genetics...
- **primary care & gynecology:** average delay/wandering 7 years – poorly characterized: acute pain / dysmenorrhea / infertility
- **imaging:** gyn/obst/radiology **specialist access at risk** with rad/obst demographics dwindling
- **interventions escalation:** treatment line in standard of care raise questions (pharmaceutical pain relief → surgical excision of lesions : **adapted physical therapies/ multimodal therapy/ therapeutic education**) / **post-op pain recurrence**



Source: <https://www.eshr.eu/Guideline/Endometriosis>

**Objective:** Reduce impact of endometriosis by improving **timely access** and **accelerated delivery of relevant diagnostic & care**

# Our approach to solve the problem

Screen

Diagnose

Stratify

Care

Follow

With patients and primary care physicians, **standardize the characterization of the disease** with pertinent listening, self-help, app-based personal behavioral assistance, precision biomarkers

Young adults / teens

QoL&PROMS

**Reduce invasiveness & optimize procedures**; predict success; reduce care avoidance by patients

Predict outcome

Long term follow-up

**Faster, more accurate imaging and reporting** for gynecologists, non-expert radiologists, surgeons

**Revisit pathway & care strategies**: identify & prove prevention strategies, experiment early line of treatment, precision surgery planning & performance – evaluate medico economic impact

adapted physical therapies

multimodal treatment

**Advance the understanding of disease**: fundamental research on uterine motility, lesion microenvironment, genetics, transcriptomics

# How this suits IHI SO1 & SO3

- Project addresses a pre-competitive issue with cross-sectorial needs
- Disease is Poorly Understood and IHI could help Recover from chronic under-investment in Women Healthcare
- Large heterogeneities exist across the EU and IHI is well designed to lower barriers to collaborative research, scale up implementation and favor dissemination across the EU
- In particular, IHI favors collaboration of industry & academic with patient representatives, healthcare system, regulators

# Outcomes and Impact

- Projects aims at accelerating access to care with faster outcomes, less traumatic and less invasive solutions
- Project will deliver to young & otherwise healthy population
- Project includes mature proposals (TRL6-8) with a work plan bringing them to market
- Project will engage with scientific societies, patient associations & regulatory for update of recommendations
- Project primarily involves R&D and products manufactured in the UE and associated countries
- Project proposal is elaborated with patient associations, scientific societies and articulated with prior consortiums (WERF, IMI-PAINCARE,...)

# Expertise and resources

- We have:
  - Diagnostic: ultrasound, MRI, Nuclear Medicine (IKOP)
  - Therapy: Pain management drug (IKOP)
  - Digital: DTx, AI (IKOP)
- We are looking for:
  - Industry partners – Diagnostic: IVD / MedTech Company, Digital / pain,
  - Therapy: Pain management (pharma, DTx), Surgical Robot, non/less-invasive care
  - Academic partners across EU & AC, esp. Specialists of pain characterization & management
  - Patient organizations, Research org., Regulator societies